Core Viewpoint - Haofan Bio's aggressive acquisition of a loss-making pharmaceutical company highlights the capacity constraints faced by biopharmaceutical firms, reflecting a broader industry challenge in managing production capabilities [1][5]. Group 1: Acquisition Details - Haofan Bio plans to invest 160 million yuan to fully acquire Hangzhou Foster Pharmaceutical in two phases, gaining 85% control after the first phase [2]. - The urgency of this acquisition stems from Haofan Bio's production capacity being fully utilized at its Anhui base, with a lengthy construction period for its new facility in Huai'an [2]. Group 2: Financial Performance of Target Company - Hangzhou Foster reported a revenue of 204 million yuan in 2024 but incurred a net loss exceeding 28 million yuan, with losses continuing into the first quarter of 2025 [3]. - Despite having a net asset value of only 46.03 million yuan, the acquisition was valued at 162 million yuan, resulting in a staggering premium of 251.52% [3]. Group 3: Strategic Intentions Behind the Acquisition - Haofan Bio's acquisition strategy includes vertical integration to enter the intermediate and active pharmaceutical ingredient sectors, thereby extending its industrial chain [4]. - The company aims to alleviate its delivery crisis by acquiring existing GMP production capacity and enhance its CDMO service capabilities through the integration of the target's quality management systems [4]. Group 4: Industry Context and Challenges - The aggressive acquisition by Haofan Bio is indicative of a broader trend in the pharmaceutical industry, where companies face "capacity anxiety" due to the high costs and long timelines associated with building production facilities [5]. - The strategy of acquiring loss-making assets can potentially open up capacity but also poses risks of integration challenges, emphasizing the need for strategic discipline and risk management in navigating industry cycles [5].
昊帆生物1.6亿豪赌产能：溢价251%吞下亏损药企，解渴还是饮鸩？